| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite Microbial Metabolite
Inosinic acid does not have a single specific biological target but is a key intermediate in purine metabolism. It is the nucleotide formed by the deamination of adenosine monophosphate (AMP) and is a precursor for the synthesis of guanosine monophosphate (GMP). It is involved in the regulation of purine nucleotide biosynthesis and acts as a signaling molecule in the nervous system. |
|---|---|
| ln Vitro |
In vitro studies of inosinic acid typically involve its use as a reference standard in nucleotide research. It is used to study purine metabolism and the regulation of nucleotide biosynthesis. The compound may be used in enzymatic assays to study the activity of enzymes involved in purine metabolism, such as IMP dehydrogenase and adenylosuccinate synthetase. It is also used as a flavor enhancer in food research.
|
| ln Vivo |
In vivo, inosinic acid is involved in purine metabolism. It is a key intermediate in the biosynthesis of adenine and guanine nucleotides. It is formed by the deamination of AMP and is converted to GMP by IMP dehydrogenase. Inosinic acid is also a precursor for the synthesis of uric acid. It acts as a signaling molecule in the nervous system.
|
| Enzyme Assay |
In vitro enzyme assays for inosinic acid typically involve studying its metabolism by enzymes involved in purine metabolism. IMP dehydrogenase assays measure the conversion of IMP to XMP. Adenylosuccinate synthetase assays measure the conversion of IMP to adenylosuccinate. The compound may also be used in assays to study the activity of other enzymes involved in nucleotide metabolism.
|
| Cell Assay |
In vitro cell-based assays using inosinic acid may involve the treatment of cultured cells with the compound to study purine metabolism. Cells may be treated with inosinic acid, and its effects on nucleotide levels and purine metabolism are measured. The compound may also be used in studies of cell proliferation and differentiation, as purine nucleotides are essential for DNA and RNA synthesis.
|
| ADME/Pharmacokinetics |
Inosinic acid has a molecular formula of C10H13N4O8P and a molecular weight of 348.21. The CAS number is 131-99-7. It is a purine nucleotide with hypoxanthine as the base. The compound is intended for research use only and should be stored according to the manufacturer's recommendations.
|
| Toxicity/Toxicokinetics |
The toxicity profile of inosinic acid is not extensively characterized, as it is a naturally occurring nucleotide. It is generally recognized as safe for use as a flavor enhancer in food. The compound is intended for research use only and is not approved for therapeutic use in humans. Standard laboratory safety practices should be followed when handling this compound.
|
| References | |
| Additional Infomation |
IMP is a purine nucleoside 5'-monophosphate with inosine as its nucleobase. It is a human metabolite, an E. coli metabolite, and a mouse metabolite. It is a purine nucleoside 5'-monophosphate, and also an inosine phosphate. It is the conjugate acid of IMP(2-). Inosine 5'-monophosphate. Inosinic acid is a purine nucleotide with inosine as its base and a glycosyl group esterified with a phosphate group. Inosinic acid is present in or produced by E. coli (K12 strain, MG1655 strain). It has also been reported to be present in fruit flies, Arabidopsis thaliana, and other organisms with relevant data. Inosinic acid is a purine ribonucleotide with inosine as its base and a glycosyl group attached to a phosphate group. Inosinic acid and its salts are used as flavor enhancers in industrial food production. In vivo, inosine monophosphate participates in purine metabolism and serves as an intermediate in the synthesis of adenine and guanine, which are precursors to the second messenger signaling molecules adenosine monophosphate (AMP) and guanine monophosphate (GMP), respectively. Inosine monophosphate is a metabolite found or produced in Saccharomyces cerevisiae. Inosine 5'-monophosphate is a purine nucleotide with hypoxanthine as its base and a glycosidic acid group esterified with a phosphate group. See also: polyinosine monophosphate (monomer); polyinosine monophosphate-polycytidylic acid (high molecular weight) (monomer); polyinosine monophosphate-polycytidylic acid (low molecular weight) (monomer).
Inosinic acid (5'-IMP; IMP; Inosine 5'-dihydrogen phosphate) (CAS 131-99-7) is a purine nucleotide which has hypoxanthine as the base and one phosphate group. It is involved in purine metabolism and acts as a signaling molecule in the nervous system. It has a molecular formula of C10H13N4O8P and a molecular weight of 348.21. |
| Molecular Formula |
C10H13N4O8P
|
|---|---|
| Molecular Weight |
348.21
|
| Exact Mass |
348.047
|
| CAS # |
131-99-7
|
| Related CAS # |
Inosinic acid (disodium)(hydrate)(1:2:X);352195-40-5;Inosinic acid-13C10,15N4 dilithium;Inosinic acid-15N4 dilithium
|
| PubChem CID |
135398640
|
| Appearance |
White to off-white solid powder
|
| Density |
2.3±0.1 g/cm3
|
| Boiling Point |
793.7±70.0 °C at 760 mmHg
|
| Flash Point |
433.8±35.7 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.882
|
| LogP |
-1.1
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
555
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=NC2=C(C(=O)N1)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O
|
| InChi Key |
GRSZFWQUAKGDAV-KQYNXXCUSA-N
|
| InChi Code |
InChI=1S/C10H13N4O8P/c15-6-4(1-21-23(18,19)20)22-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17/h2-4,6-7,10,15-16H,1H2,(H,11,12,17)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
|
| Chemical Name |
[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~125 mg/mL (~358.98 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (143.59 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8718 mL | 14.3592 mL | 28.7183 mL | |
| 5 mM | 0.5744 mL | 2.8718 mL | 5.7437 mL | |
| 10 mM | 0.2872 mL | 1.4359 mL | 2.8718 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT06319235
Conditions:Surgical Site Infection|Staphylococcus Aureus Infection|Pseudomonas Aeruginosa Infection|Bacterial Infections|Surgical Wound InfectionLink: https://clinicaltrials.gov/ct2/show/NCT04219124
Conditions:Type 2 DiabetesProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
